Morgan Stanley Infinity Pharmaceuticals, Inc. Transaction History

Morgan Stanley

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$0.14 - $0.24 $2 - $3	-15 Reduced 0.03%	45,025 $9,000
Q1 2023 May 15, 2023	SELL	$0.16 - $0.74 $500 - $2,313	-3,126 Reduced 6.49%	45,040 $7,000
Q4 2022 Feb 14, 2023	SELL	$0.46 - $1.21 $527 - $1,386	-1,146 Reduced 2.32%	48,166 $26,000
Q3 2022 Nov 14, 2022	SELL	$0.59 - $1.7 $106,141 - $305,831	-179,901 Reduced 78.49%	49,312 $59,000
Q2 2022 Oct 27, 2022	SELL	$0.49 - $1.2 $9,292 - $22,756	-18,964 Reduced 7.64%	229,213 $144,000
Q2 2022 Aug 15, 2022	SELL	$0.49 - $1.2 $9,292 - $22,756	-18,964 Reduced 7.64%	229,213 $144,000
Q1 2022 Oct 27, 2022	BUY	$0.85 - $2.4 $16,119 - $45,513	18,964 Added 8.27%	248,177 $282,000
Q1 2022 May 13, 2022	BUY	$0.85 - $2.4 $125,398 - $354,067	147,528 Added 146.58%	248,177 $282,000
Q4 2021 Feb 14, 2022	SELL	$1.86 - $3.36 $497,814 - $899,277	-267,642 Reduced 72.67%	100,649 $227,000
Q3 2021 Nov 15, 2021	BUY	$1.52 - $3.82 $559,802 - $1.41 Million	368,291 New	368,291 $1.26 Million

1.26M

Ticker INFI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 89,277,904
Description
Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of met...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.